Back to Cardiology
Cardiologyv2017Evidence-Based

GARFIELD-AF Risk Score

The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.

Clinical Input Parameters

years
Range: 18 — 120 years
kg
Range: 30 — 300 kg
bpm
Range: 30 — 250 bpm
mmHg
Range: 40 — 150 mmHg
Clinical Assessment
Awaiting Parameters
risk predictions
—percentage
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The GARFIELD-AF Risk Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Complex regression model with 16 variables predicting simultaneous risks of mortality, ischemic stroke/systemic embolism, and major bleeding at 1 and 2 years using validated coefficients from GARFIELD-AF registry

Clinical Pearls & Practice Notes

  • The GARFIELD-AF score simultaneously predicts three key outcomes: mortality, ischemic stroke/systemic embolism, and major bleeding
  • Risk predictions are provided for both 1-year and 2-year time horizons
  • The score has been validated in both anticoagulated and non-anticoagulated patients
  • This tool incorporates contemporary clinical variables and is based on a large international registry
  • Unlike single-outcome scores (CHA2DS2-VASc, HAS-BLED), GARFIELD-AF provides integrated risk assessment
  • The score helps balance anticoagulation benefits against bleeding risks in individual patients
  • Regular re-evaluation is recommended as clinical status changes may affect risk predictions

Evidence & Literature Citations

  1. Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.
  2. Apenteng PN, Murray ET, Holder R, et al. An international longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011.
  3. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307-314. doi: 10.1136/heartjnl-2016-309832.

Score Interpretation Ranges

Low Risk0 – 2 pts

Low risk across all outcomes

Moderate Risk2 – 5 pts

Moderate risk requiring careful monitoring

High Risk5 – 100 pts

High risk requiring intensive management

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.